[HTML][HTML] The sphingosine‐1‐phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo
YY Lan, A De Creus, BL Colvin, M Abe… - American Journal of …, 2005 - Elsevier
The pro‐drug FTY720 is undergoing phase III clinical trials for prevention of allograft
rejection. After phosphorylation, FTY720 targets the G protein‐coupled–sphingosine‐1‐
phosphate receptor 1 (S1PR1) on lymphocytes, thereby inhibiting their egress from
lymphoid organs and their recirculation to inflammatory sites. Potential effects on dendritic
cell (DC) trafficking have not been evaluated. Here, we demonstrate the expression of all
five S1PR subtypes (S1PR1–5) by murine DCs. Administration of FTY720 to C57BL/10 mice …
rejection. After phosphorylation, FTY720 targets the G protein‐coupled–sphingosine‐1‐
phosphate receptor 1 (S1PR1) on lymphocytes, thereby inhibiting their egress from
lymphoid organs and their recirculation to inflammatory sites. Potential effects on dendritic
cell (DC) trafficking have not been evaluated. Here, we demonstrate the expression of all
five S1PR subtypes (S1PR1–5) by murine DCs. Administration of FTY720 to C57BL/10 mice …